

Q4 FY24 Earnings Preview - Pharma & Healthcare

Q4 typically sees weakness in domestic acute business on account of low seasonality. US business is expected to exhibit moderate growth as operating environment remains presumably benign. India business for most companies especially chronic focused ones would grow 9-11% YoY while acute heavy ones might have to endure mid-single digit growth. Large companies like Lupin, Dr Reddy's would continue to benefit from product specific boost like Spiriva and Revlimid (some seasonal weakness not ruled out) while smaller ones would have to rely on existing business to drive growth in US. Diagnostic players would see broad volume range with Vijaya again leading the pack. We reckon Torrent, Lupin and Ajanta could report better than expected numbers while Alkem and JB Chem likely to disappoint extant consensus expectations.

- **Ajanta Pharma** - Some lingering impact of MetXL price cut which was effective from Feb'23. Africa branded to recover partly in primary sales while Asia branded seen up ~10% YoY. US to remain steady with moderate ~2% growth QoQ. Freight cost impact seen <1% on EBIDTA
- **Torrent Pharma** - Domestic business to chug along at 10% YoY growth while Brazil should also see a double-digit rise; US to be steady at US\$34mn before ramp up expected from Dahej in H2 FY25. Margin to come in strong at over 34% as gross margin improve due to better mix.
- **Aurobindo** - US\$20mn impact due to shutting down of aseptic and septic lines at Eugia 3; aseptic lines to come back gradually in April. Revlimid would be a key driver to offset some of the US revenue loss YoY. Europe to see ebbing of one-time revenue hit while ROW markets would see benefit of Indonesian acquisition
- **Vijaya Diagnostics** - About 15% topline growth to continue driven by 13-14% rise in patient volumes on a like-to-like basis. Including PH for full quarter results in 23% growth on reported basis. Kolkata, Mehbubnagar, Tirupati and Gulburga are some of the hubs added YoY and should add to growth. Reckon no major costs incurred QoQ; addition of Ongole hub in Q1 FY25. Margin can be around or above 40% as PH Diagnostics integration costs would not be meaningful.
- **Metropolis** - A 5% price hikes across B2C portfolio which is 55% of the revenue translates into ~2.5% price hike from January. Volume growth is likely to be in double digit while PPP contract went off in Feb so impact would be ~40 days for the quarter or (higher margin) ~Rs100mn sitting in the base last year. Q3 had 0.9% impact due to provision for bad debt
- **Indoco** - Domestic growth ~6% lower than IPM in Q4; Remediation costs not much different from Q3. US sales continue to be affected due to inability to supply. Europe – paracetamol overstocking behind but ramp up to H1 levels to come about in Q1 FY25
- **Alkem** - Q4 margin would be ~13% or thereabout vs 12.5% in Q4 FY23; R&D would be on higher side as Q4 normally sees higher filings which would offset the lower input costs YoY. US - Suprep still not launched while domestic growth might end FY24 on a weak note at 4-5% YoY growth (slightly higher base in Q4 FY23)
- **Sun Pharma** - Expect steady up move in US specialty business with sustained momentum in Taro; ROW had US\$20mn payment from Almirall in Q3 which would be presumably absent in Q4. Domestic growth of ~10% YoY.
- **JB Chem** - Looking at ~10% growth in domestic business on a like-to-like basis adjusting for Razel inventory and excluding ophthalmology portfolio. Can add ~Rs300mn from ophthalmology products translating into mid-teens growth in domestic business on reported basis. Ophthalmology products would come with very low gross and EBIDTA margin which would drag overall EBIDTA. Exports seen flat due to exit of SA tender business in Q2 FY24 while being part of base quarter YoY. CMO seen at sub Rs1bn and down 8% YoY
- **Gland Pharma** - One-offs in Cenexi expenses to the tune of Euro2mn would recede while moderate growth in US presumed QoQ. Addition of Enoxaparin supplies in US might be margin dilutive
- **Lupin** - Spiriva expected to ramp up after 2 quarters as revenues pick up pace to match prescription trends an expectation outlined in previous call. Other products like Chantix, Dronedarone (first generic) and traction in earlier ophthalmic launches like Prolensa should support QoQ momentum. Domestic business to remain strong YoY while better mix to ensure margin cross 20%.

BHAVESH GANDHI
Lead Analyst
bhavesh.gandhi@ysil.in




Exhibit 1: Pharma & Healthcare- Earnings expectation snapshot

Co. name (Rs mn)	Revenue			EBITDA			PAT			Remarks
	Q4 FY24	YoY (%)	QoQ (%)	Q4 FY24	YoY (bps)	QoQ (bps)	Q4 FY24	YoY (%)	QoQ (%)	
Dr Reddy's	70,460	11.6	(2.6)	19,569	263	(33)	13,159	37.1	(4.7)	Revlimid could be flat or marginally lower as Q4 is traditionally a weak period for ordering (as per innovator BMS comments). India business to see ~10% YoY adjusted for Rs2.6bn of non core brands divested in Q4 FY23. Margin tad lower on US decline QoQ
Aurobindo Pharma	73,255	13.2	(0.4)	15,193	526	(104)	8,038	59.0	(14.1)	US\$20mn impact due to shutting down of aseptic and septic lines at Eugia 3; aseptic lines to come back gradually in April. Revlimid would be a key driver to offset some of the US revenue loss YoY. Europe to see ebbing of one-time revenue hit while ROW markets would see benefit of Indonesian acquisition
Sun Pharma	118,585	8.5	(4.2)	28,719	(167)	(286)	20,379	2.7	(19.3)	Expect steady up move in US specialty business with sustained momentum in Taro; ROW had US\$20mn payment from Almirall in Q3 which would be presumably absent in Q4. Domestic growth of ~10% YoY.
Lupin	51,459	16.2	(1.0)	10,731	722	119	5,946	152.0	(3.0)	Spiriva expected to ramp up after 2 quarters as revenues pick up pace to match prescription trends, an expectation outlined in Q3 call. Other launches like Chantix, Dronedarone (first generic) and traction in earlier ophthalmic launches like Prolensa should support QoQ momentum. Domestic business to remain strong YoY while better mix to ensure margin cross 20%
Torrent Pharma	27,547	10.6	0.8	9,248	439	176	4,154	44.7	(6.2)	Domestic business to chug along at 10% YoY growth while Brazil should also see a double digit rise; US to be steady at US\$34mn before ramp up expected from Dahej in H2 FY25. Margin to come in strong at over 34% as gross margin improves due to better mix
Ajanta Pharma	10,713	21.5	(3.1)	2,845	716	(186)	1,876	57.0	(10.7)	Some lingering impact of MetXL price cut which was effective from Feb'23. Africa branded to recover partly in primary sales while Asia branded seen up ~10% YoY. US to remain steady with moderate ~2% growth QoQ while freight to shave off <100bps from margin (due to large Iraq presence)
Alkem	30,817	6.2	(7.3)	4,113	118	(794)	3,592	430.7	(40.6)	Should end the year with ~17% guided margin number and Q4 would be ~13% or thereabout vs 12.5% in Q4 FY23; R&D would be on higher side as Q4 normally sees accelerated filings that would offset lower input costs YoY. US - Suprep still not launched while domestic business might end FY24 on a weak note at +4-5% YoY (slightly higher base in Q4 FY23)
Indoco Remedies	4,285	0.1	(6.7)	530	(277)	(133)	159	(38.2)	(2.2)	Domestic growth ~6% lower than IPM in Q4; Remediation costs not much different from Q3 US sales continue to be affected due to inability to supply. Europe - paracetamol overstocking behind but ramp up to H1 levels to come about in Q1 FY25
IPCA	19,913	31.7	(3.0)	3,117	368	(49)	1,342	75.3	(25.4)	Branded growth to rebound after shipments resume in CIS and also based on 6-7% YoY growth in FY24 resulting in a strong QoQ finish. Domestic growth to be ~11% while API business to remain subdued for 1 more quarter. Generic business expected to clock ~15% YoY growth, building conservatively lower than 9m FY24 growth


Co. name (Rs mn)	Revenue			EBITDA			PAT			Remarks
	Q4 FY24	YoY (%)	QoQ (%)	Q4 FY24	YoY (bps)	QoQ (bps)	Q4 FY24	YoY (%)	QoQ (%)	
JB Chem	8,230	8.0	(2.5)	1,695	(305)	(724)	824	(6.0)	(38.3)	Looking at ~10% growth in domestic business on a like-to-like basis adjusting for Razel inventory and excluding ophthalmology portfolio. Can add ~Rs300mn from ophthalmology products translating into mid-teens growth in domestic business on reported basis. Ophthalmology products would come with very low gross and EBIDTA margin which would drag overall EBIDTA. Exports seen flat due to exit of SA tender business in Q2 FY24 while being part of base quarter YoY. CMO seen at sub Rs1bn and down 8% YoY
Syngene	10,453	5.1	22.5	3,255	(87)	256	1,635	(8.5)	46.6	Basis Q3 revised guidance, expect weak end to FY24 with 5% YoY growth in Q4. With presumed pressure emanating from weak biotech orders, biologics manufacturing could be weak translating into actually better gross margin mix
Gland Pharma	16,064	104.6	4.0	3,958	318	157	2,236	184.1	16.5	One-offs in Cenexi expenses to the tune of Euro2mn would recede while moderate growth in US presumed QoQ. Addition of Enoxaparin supplies in US might be margin dilutive
Alembic Pharma	15,812	12.4	(3.0)	2,566	114	(11)	1,554	1.9	(13.9)	US to see 5 launches coupled with benign operating environment which might offset lack of major new approvals. Domestic growth seen healthy at ~9% YoY while gross margin might taper off somewhat QoQ as domestic business on back of weak domestic seasonality
Sequent Scientific	3,758	2.5	14.1	428	788	284	66	(107.3)	(20.4)	Topline growth would be low single digit as rationalization and exits would have an impact YoY though building in ~11% margin in line with company guidance of double digit exit from Q4
Dr Lal Pathlabs	5,254	7.0	(2.5)	1,306	131	(123)	747	31.7	(8.1)	Volume growth presumption of ~5% YoY coupled with some benefit YoY of price hike in Feb'23 which would result in mid to high single digit growth YoY. No immediate benefits of going deeper in Tier 3 and 4 locations. Gross margin to rise ~150-200bps YoY
Metropolis Health	3,025	7.1	3.9	751	(6)	254	342	2.4	25.8	We understand company has taken a 5% price hikes across B2C portfolio which is 55% of the revenue translating in to ~2.5% price hike from January. Volume growth is likely to be in double digit while PPP contract went off in Feb so impact would be ~40 days for the quarter or (higher margin) ~Rs100mn sitting in the base last year
Vijaya Diagnostic	1,494	23.5	12.6	597	(61)	55	305	10.8	17.1	About 15% topline growth to continue driven by 13-14% rise in patient volumes on a like-to-like basis. Including PH for full quarter results in 23% growth on reported basis. Kolkata, Mehbubnagar, Tirupati and Gulburga are some of the hubs added YoY and should add to growth. Reckon no major costs incurred QoQ; addition of Ongole hub in Q1 FY25. Margin can be around or above 40% as PH Diagnostics integration costs would not be meaningful.

Exhibit 2: Trend in domestic growth across pharma cos, % YoY




Source: Companies, YES Sec

Exhibit 3: Trend in US growth across pharma cos, % QoQ




Source: Companies, YES Sec

Exhibit 4: Pharma margin mostly up YoY as base quarter had RM cost surge




Source: Companies, YES Sec

Exhibit 5: Lupin to lead large pharma growth in markets excluding India and US




Source: Companies, YES Sec

Exhibit 6: Diagnostics - Metropolis margin weak due to PPP contract revs in base




Source: Companies, YES Sec

Exhibit 7: CDMO - Low revenue growth to keep Syngene margin under leash




Source: Companies, YES Sec

Exhibit 8: Diagnostics - Implicit vol assumption in Q4 revenue estimates



Source: Companies, YES Sec

Exhibit 9: API segment - 2 key players still struggling YoY



Source: Companies, YES Sec

DISCLAIMER

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

The information and opinions in this report have been prepared by YSL and are subject to change without any notice. The report and information contained herein are strictly confidential and meant solely for the intended recipient and may not be altered in any way, transmitted to, copied or redistributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of YSL.

The information and opinions contained in the research report have been compiled or arrived at from sources believed to be reliable and have not been independently verified and no guarantee, representation of warranty, express or implied, is made as to their accuracy, completeness, authenticity or validity. No information or opinions expressed constitute an offer, or an invitation to make an offer, to buy or sell any securities or any derivative instruments related to such securities. Investments in securities are subject to market risk. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Investors should note that each security's price or value may rise or fall and, accordingly, investors may even receive amounts which are less than originally invested. The investor is advised to take into consideration all risk factors including their own financial condition, suitability to risk return profile and the like, and take independent professional and/or tax advice before investing. Opinions expressed are our current opinions as of the date appearing on this report. Investor should understand that statements regarding future prospects may not materialize and are of general nature which may not be specifically suitable to any particular investor. Past performance may not necessarily be an indicator of future performance. Actual results may differ materially from those set forth in projections. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Technical Analysis reports focus on studying the price movement and trading turnover charts of securities or its derivatives, as opposed to focussing on a company's fundamentals and opinions, as such, may not match with reports published on a company's fundamentals.

YSL, its research analysts, directors, officers, employees and associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject

YSL and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. YES Securities (India) Limited distributes research and engages in other approved or allowable activities with respect to U.S. Institutional Investors through SEC 15a-6 rules and regulations under an exclusive chaperone arrangement with Brasil Plural Securities LLC. The views and sentiments expressed in this research report and any findings thereof accurately reflect YES Securities (India) Limited analyst's truthful views about the subject securities and or issuers discussed herein. YES Securities (India) Limited is not registered as a broker-dealer under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC. For questions or additional information, please contact Gil Aikins (gil.aikins@brasilplural.com) or call +1 212 388 5600.

This Research Report is the product of YES Securities (India) Limited. YES Securities (India) Limited is the employer of the research analyst(s) who has prepared the research report. YES Securities (India) Limited is the employer of the YES Securities (India) Limited Representative who is responsible for the report, are responsible for the content of the YES Securities (India) Limited Research Report; any material conflicts of interest of YES Securities (India) Limited in relation to the issuer(s) or securities discussed in the YES Securities (India) Limited Research Report. This YES Securities (India) Limited Research Report is distributed in the United States through Brasil Plural Securities LLC (BPS). The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and is/ are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution by YES Securities (India) Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity. Transactions in securities discussed in this research report should be effected through Brasil Plural Securities LLC (BPS) or another U.S. registered broker dealer/Entity as informed by YES Securities (India) Limited from time to time.

YES Securities (India) Limited

Registered Address: 2nd Floor, North Side, YES BANK House, Off Western Express Highway, Santacruz East, Mumbai - 400 055, Maharashtra, India.

Correspondence Address: 7th Floor, Urmi Estate Tower A, Ganpatrao Kadam Marg, Opp. Peninsula Business Park, Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

✉ research@ysil.in | Website: www.yesinvest.in

Registration Nos.: CIN: U74992MH2013PLC240971 | SEBI Single Registration No.: NSE, BSE, MCX & NCDEX : INZ000185632 | Member Code: BSE - 6538, NSE - 14914, MCX - 56355 & NCDEX - 1289 | CDSL & NSDL: IN- DP-653-2021 | MERCHANT BANKER: INM000012227 | RESEARCH ANALYST: INH000002376 | INVESTMENT ADVISER: INA000007331 | Sponsor and Investment Manager to YSL Alternates Alpha Plus Fund (CAT III AIF) SEBI Registration No.: IN/AIF3/20-21/0818 | AMFI ARN Code - 94338.

Details of Compliance Officer: Name: Aditya Goenka,
Email id: compliance@ysil.in, **Contact No:** 022- 65078127 (Extn: 718127)

Grievances Redressal Cell: customer.service@ysil.in/igc@ysil.in

DISCLOSURE OF INTEREST

Name of the Research Analyst : Bhavesh Gandhi

The analyst hereby certifies that opinion expressed in this research report accurately reflect his or her personal opinion about the subject securities and no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendation and opinion expressed in this research report.

Sr. No.	Particulars	Yes/No
1	Research Analyst or his/her relative's or YSL's financial interest in the subject company(ies)	No
2	Research Analyst or his/her relative or YSL's actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report	No
3	Research Analyst or his/her relative or YSL has any other material conflict of interest at the time of publication of the Research Report	No
4	Research Analyst has served as an officer, director or employee of the subject company(ies)	No
5	YSL has received any compensation from the subject company in the past twelve months	No
6	YSL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
7	YSL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
8	YSL has received any compensation or other benefits from the subject company or third party in connection with the research report	No
9	YSL has managed or co-managed public offering of securities for the subject company in the past twelve months	No
10	Research Analyst or YSL has been engaged in market making activity for the subject company(ies)	No

Since YSL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months or associates of YSL may have managed or co-managed public offering of securities in the past twelve months of the subject company(ies) whose securities are discussed herein.

Associates of YSL may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.

Analyst Signature

RECOMMENDATION PARAMETERS FOR FUNDAMENTAL REPORTS

Analysts assign ratings to the stocks according to the expected upside/downside relative to the current market price and the estimated target price. Depending on the expected returns, the recommendations are categorized as mentioned below. The performance horizon is 12 to 18 months unless specified and the target price is defined as the analysts' valuation for a stock. No benchmark is applicable to the ratings mentioned in this report.

BUY: Upside greater than 20% over 12 months

ADD: Upside between 10% to 20% over 12 months

NEUTRAL: Upside between 0% to 10% over 12 months

REDUCE: Downside between 0% to -10% over 12 months

SELL: Downside greater than -10% over 12 months

NOT RATED / UNDER REVIEW

ABOUT YES SECURITIES (INDIA) LIMITED

YES Securities (India) Limited ("YSL") is a wholly owned subsidiary of YES BANK LIMITED. YSL is a Securities and Exchange Board of India (SEBI) registered Stock broker holding membership of National Stock Exchange (NSE), Bombay Stock Exchange (BSE), Multi Commodity Exchange (MCX) & National Commodity & Derivatives Exchange (NCDEX). YSL is also a SEBI-registered Category I Merchant Banker, Investment Adviser and Research Analyst. YSL is also a Sponsor and Investment Manager of Alternate Investment Fund - Category III (YSL Alternates) and AMFI registered Mutual Fund Distributor. The Company is also a registered Depository Participant with CDSL and NSDL. YSL offers, inter alia, trading/investment in equity and other financial products along with various value added services. We hereby declare that there are no disciplinary actions taken against YSL by SEBI/Stock Exchanges.